- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05010525
A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors (REACH)
A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Shimin Sun
- Phone Number: 13701803117
- Email: jasmine.sun@antengene.com
Study Contact Backup
- Name: Xiaobei He
- Phone Number: 13916910751
- Email: xiaobei.he@antengene.com
Study Locations
-
-
Anhui
-
Bengbu, Anhui, China, 233099
- The First Affiliated Hospital of Bengbu Medical College Bengbu
-
-
Chonqing
-
Chongqing, Chonqing, China, 400000
- Chongqing Cancer Hospital
-
-
Fujian
-
Xiaomen, Fujian, China, 361000
- The First Affiliated Hospital of Xiamen University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610044
- West China Hospital, Sichuan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Understand and voluntarily sign informed Consent (ICF) prior to any assessment/procedure related to study.
- Age ≥18 years at ICF signature.
- Estimated life expectancy of minimum of 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at ICF signature.
- Subjects must have at least one measurable lesion as defined by RECIST version 1.1.
- Females of childbearing potential must agree to use effective contraception from the time ICF signature until 180 days after the last dose. Females of childbearing potential include those who are premenopausal and those who are 2 years postmenopausal. Blood pregnancy tests must be negative for female of childbearing potential must have a negative serum pregnancy test at Screening.
Inclusion Criteria Only for Phase Ib study (Dose Escalation and Expansion phase)
1. Histological or cytological confirmation of a solid tumor, and have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or have no standard therapy(ies) exists.
Inclusion Criteria Only for Phase II
- Penile squamous cell carcinomas confirmed by cytology or histology cannot be excised by radical surgery, or postoperative recurrence or metastasis which is not suitable for platinum chemotherapy or platinum resistance or platinum failure.
- Nasopharyngeal carcinoma
Exclusion Criteria:
Subjects with any of the following conditions will not be enrolled in this study.
- Central nervous system (CNS) metastases and involvement.
- A history of bone marrow or organ transplantation.
- Prior ATG-016 administration or other XPO1 inhibitor treatment.
- Known to be allergic to the active or inactive ingredients of ATG-016 or drugs with similar chemical structure, or the subject is hypersensitive.
- Prior therapy with any investigational drugs or systemic anticancer treatment (eg, a period of 5 'half-lives' of drugs, whichever is longer) within 28 days at the time of ICF signature.
- Received extensive radiation within 28 days at the time of ICF signature or expect to undergo radical radiotherapy during the study period.
- Received major surgery within 28 days at the time of ICF signature or expect to proceed a major surgical treatment during the study period.
- Any toxicities unresolved to Grade 1 or baseline from prior anti-tumor therapy (According to NCI-CTCAE 5.0) with the exception of alopecia, within 28 days at the time of ICF signature.
- Any uncontrolled active infection requiring parenteral treatment of antibiotics, antivirals, or antifungals at the time of ICF signature or within one week of Cycle 1 Day 1 (C1D1). Active hepatitis B virus (HBV) infection (Hepatitis B surface antigen [HBsAg] positive) or active HCV infection (HCV-RNA positive at screening).
- A history of HIV infection and/or acquired immunodeficiency syndrome.
- Received immunosuppressive medication within 14 days at the time of ICF signature.
- Cardiovascular diseases of clinical significance
- Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
- Have a history of another primary malignancy within 5 years prior to starting study treatment, with following exceptions: malignancy tumors treated by radical therapy and have not been recurred, such as carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, papillary thyroid carcinoma, etc.
- Inability or unwillingness to comply with the requirement for oral drug administration, or presence of a gastrointestinal diseases or other clinical conditions that would compromise the absorption of study drug, eg, refractory nausea and vomiting, inability to swallow the formulated product, or previous significant bowel resection, etc.
- Active or a history of bleeding within 6 months.
- Received any live attenuated vaccination within 28 days at the signature of ICF.
- Judgment by the investigator that the subject should not participate in the study by consideration of the complications or other conditions which might affect their adherence to the protocol.
- Female subjects who are pregnant or lactating.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ATG-016-20mg
20 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
|
48 patients enrolled, orally, each 3 week (21-day) a cycle
|
Experimental: ATG-016-35mg
35 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
|
48 patients enrolled, orally, each 3 week (21-day) a cycle
|
Experimental: ATG-016-50mg
50 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
|
48 patients enrolled, orally, each 3 week (21-day) a cycle
|
Experimental: ATG-016-65mg
65 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
|
48 patients enrolled, orally, each 3 week (21-day) a cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MTD in Phase I
Time Frame: 16 months
|
MTD will be evaluated using the NCI-CTCAE, Version 5.0
|
16 months
|
RP2D in Phase I
Time Frame: 16 months
|
RP2D will be determined under the guidance of the SRC.
|
16 months
|
AEs
Time Frame: 25 months
|
Toxicity will be graded according to the NCI CTCAE, Version 5.0.
|
25 months
|
SAEs
Time Frame: 25 months
|
Toxicity will be graded according to the NCI CTCAE, Version 5.0.
|
25 months
|
ORR in Phase II
Time Frame: 25 months
|
Based on 2006 IWG Response Criteria, evaluated by IRC: ORR (CR + PR + mCR)
|
25 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate (DCR) in Phase I/II
Time Frame: 16 months
|
DCR (CR + PR + mCR + HI + SD)
|
16 months
|
Duration of Response (DOR) in Phase I/II
Time Frame: 12 months
|
To evaluate duration of response
|
12 months
|
Overall Survival (OS)
Time Frame: 12 months
|
The estimates of Kaplan-Meier
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yongsheng Wang, PhD, Guoxue lane, Chengdu, Sichuan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATG-016-ST-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
Clinical Trials on ATG-016
-
Shanghai Antengene Corporation LimitedTerminated
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedHealthy SubjectsUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedHealthy SubjectsUnited States
-
Shenzhen Fifth People's HospitalRecruiting
-
Aptevo TherapeuticsCompletedChronic Lymphocytic Leukemia (CLL) | Non-Hodgkin's Lymphoma (NHL)United States
-
University of North Carolina, Chapel HillCompletedMalocclusion | Tooth Crowding | Dental CrowdingUnited States
-
Aptevo TherapeuticsTerminatedChronic Lymphocytic Leukemia | Peripheral T-cell LymphomaUnited States
-
Aptevo TherapeuticsCompletedChronic Lymphocytic Leukemia (CLL)United States, Austria, Germany, Poland, Spain
-
Antengene CorporationTerminatedRelapsed/Refractory Diffuse Large B-cell LymphomaChina